Stoke Therapeutics, Inc. (STOK) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Stoke Therapeutics' second quarter 2025 conference call. I'm Tommy Leggett, chief financial officer at Stoke. Joining me for prepared remarks are Ian Smith, our interim chief executive officer, Dr. Barry Tico, chief medical officer, and Dr. Kimberly Parkerson, head of neurology clinical development. In addition, Jason Hoyt, our chief patient officer, will participate in Q&A. As a reminder, today's webcast slides are available in the investor section of our website. This webcast is being recorded and will be available for replay later today. Before we begin, please note that today's discussion includes forward-looking statements. These are subject to risks and uncertainties, and actual results may differ materially. Please refer to the filings of the SEC for additional information. With that, I'll turn the call over to Ian. Welcome, everyone, and thank you for joining us today. I've been working with Stoke Therapeutics for two years as a director and advisor, more recently as the CEO. It has been a great opportunity to get to know the team, the medicines, and the disease areas, and to support the company through this growth period. The key priority is obviously Dravet syndrome and Zoriba-Nursen, as we work to deliver a disease-modifying medicine to patients. What we're seeing with Zoriba-Nursen may be new to the field of epilepsy, but I'm struck with the familiarity of the feeling of being part of something very special, again, which is creating a new -in-class disease-modifying medicine for patients who desperately need it, potentially changing the lives of these children suffering from Dravet syndrome. Let me start by saying that Stoke is in a strong growth position, defined by a late-stage registrational medicine, well-capitalized bala...